€197.30
0.85%
Brüssel, Aug 22, 05:35 pm CET
ISIN
BE0003739530
Symbol
UCB

UCB Stock price

€197.30
+24.75 14.34% 1M
+15.20 8.35% 6M
+5.10 2.65% YTD
+35.75 22.13% 1Y
+124.96 172.74% 3Y
+96.20 95.15% 5Y
+132.71 205.47% 10Y
+150.69 323.30% 20Y
Brüssel, Closing price Fri, Aug 22 2025
-1.70 0.85%
ISIN
BE0003739530
Symbol
UCB
Industry

Key metrics

Basic
Market capitalization
€37.6b
Enterprise Value
€38.5b
Net debt
€866.0m
Cash
€2.0b
Shares outstanding
190.0m
Valuation (TTM | estimate)
P/E
28.8 | 26.6
P/S
5.5 | 5.6
EV/Sales
5.6 | 5.7
EV/FCF
32.5
P/B
3.9
Dividends
DPS
€1.39
Yield 1Y | 5Y
0.7% | 1.2%
Growth 1Y | 5Y
2.2% | 2.3%
Payout 1Y | 3Y
24.9% | 42.5%
Increased
16 Years
Financials (TTM | estimate)
Revenue
€6.8b | €6.8b
EBITDA
€2.5b | €2.1b
EBIT
€1.8b | €1.4b
Net Income
€1.3b | €1.4b
Free Cash Flow
€1.2b
Growth (TTM | estimate)
Revenue
25.6% | 9.9%
EBITDA
104.5% | 40.5%
EBIT
259.0% | 62.9%
Net Income
455.0% | 32.3%
Free Cash Flow
108.3%
Margin (TTM | estimate)
Gross
73.4%
EBITDA
35.9% | 30.9%
EBIT
26.6%
Net
19.5% | 20.9%
Free Cash Flow
17.3%
Financial Health
Equity Ratio
57.8%
Return on Equity
10.6%
ROCE
13.7%
ROIC
14.2%
Debt/Equity
0.3
More
EPS
€6.9
FCF per Share
€6.2
Short interest
-
Employees
9k
Rev per Employee
€670.0k
Show more

Is UCB a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

UCB Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a UCB forecast:

19x Buy
76%
6x Hold
24%

Analyst Opinions

25 Analysts have issued a UCB forecast:

Buy
76%
Hold
24%

Financial data from UCB

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
6,848 6,848
26% 26%
100%
- Direct Costs 1,823 1,823
4% 4%
27%
5,025 5,025
36% 36%
73%
- Selling and Administrative Expenses 2,565 2,565
28% 28%
37%
- Research and Development Expense 1,852 1,852
12% 12%
27%
2,456 2,456
104% 104%
36%
- Depreciation and Amortization 636 636
8% 8%
9%
EBIT (Operating Income) EBIT 1,820 1,820
259% 259%
27%
Net Profit 1,332 1,332
455% 455%
19%

In millions EUR.

Don't miss a Thing! We will send you all news about UCB directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Head office Belgium
CEO Jean-Christophe Tellier
Employees 9,215
Founded 1925
Website www.ucb.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today